Cytopia strengthens scientific team
This article was originally published in Scrip
Cytopia (Australia) has appointed Dr Devron Averett chief scientific advisor. He will work closely with the company's executive management team, on a part-time basis during this year, to provide scientific leadership and guidance. He has held leadership roles at Glaxo Wellcome and Burroughs Wellcome and, in recent years, at Valeant Pharmaceuticals International and Anadys Pharmaceuticals, a company he co-founded. Cytopia is also consolidating its North American operations in Woodside, California, and closing the Rensselaer, New York, office, which is currently led by Dr Shreefal Mehta as vice-president of business and corporate development. Dr Mehta has chosen not to relocate to the west coast and will leave the company at the end of July. Richard Haiduck, who has been working with the company in a strategic consulting role, has been appointed as chief business advisor, with responsibility for Cytopia's global business and corporate development.
You may also be interested in...
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.